Ahmadshah Mirkhel, MD
Nephrology · Fairfax, VANPI 1790729317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $869, 2.7 times the $321 reported in 2019.
Across 111 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$473
- AstraZeneca$261
- Akebia Therapeutics Inc$249
- Mallinckrodt Hospital Products Inc.$188
- Ardelyx, Inc.$163
- Amgen$160
- plus $1K from 20 others
Across 84 payments — averaging $10,704 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$684K
- Bayer$121K
- CSL Behring$42K
- Hoffmann-la Roche Limited$35K
- Biogen$16K
What the payments were for
- Food & beverage$2,47296%
- Education$1144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $473 |
| AstraZeneca(2 entities) | 13 | $261 |
| Akebia Therapeutics Inc | 8 | $249 |
| Mallinckrodt Hospital Products Inc. | 7 | $188 |
| Ardelyx, Inc. | 6 | $163 |
| Amgen(2 entities) | 7 | $160 |
| Otsuka America Pharmaceutical, Inc. | 4 | $147 |
| ANI Pharmaceuticals, Inc. | 4 | $113 |
| Calliditas Therapeutics US Inc. | 2 | $101 |
| Travere Therapeutics, Inc. | 6 | $93 |
| GSK | 3 | $80 |
| Aurinia Pharma U.S., Inc. | 3 | $78 |
| Fresenius USA Marketing, Inc. | 4 | $66 |
| OPKO Pharmaceuticals, LLC | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Mallinckrodt Enterprises LLC | 1 | $49 |
| Lilly USA, LLC | 2 | $47 |
| Vifor Pharma, Inc. | 2 | $37 |
| Cormedix Inc. | 1 | $30 |
| Bayer | 2 | $30 |
| Genentech USA, Inc. | 1 | $25 |
| Recor Medical Inc | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Biomerieux Inc | 1 | $12 |
How this compares
$2,587 in reported general payments places this provider in the 75th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 94 | $134,527 |
| FarxigaDapagliflozin Propanediol | 70 | $73,286 |
| VeltassaPatiromer Calcium Sorbitex | 27 | $28,698 |
| ProsolParenteral Amino Acid 20% No.1 | 114 | $14,694 |
| EpogenEpoetin Alfa | 19 | $13,984 |
| Sevelamer Carbonate | 19 | $4,905 |
| RetacritEpoetin Alfa-Epbx | 13 | $4,084 |
| Losartan Potassium | 204 | $1,881 |
| Chlorthalidone | 82 | $1,853 |
| Bumetanide | 34 | $1,588 |
| Sodium Polystyrene Sulfonate | 20 | $1,535 |
| Calcium Acetate | 15 | $1,391 |
| Allopurinol | 97 | $1,111 |
| Calcitriol | 64 | $1,041 |
| Telmisartan | 30 | $908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $261 | $73,28670 claims |
| AmgenEpogen | $160 | $13,98419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 298 nephrology providers in Virginia.
Other nephrology in Fairfax
- Reza ZonoziFairfax$262K
- Renuka SothinathanFairfax$68K
- Ali AssefiFairfax$64K
- Kinjal PatelFairfax$31K
- Paul ModlingerFairfax$18K
- Magnus IkhinmwinFairfax$11K
- Renu Regunathan-ShenkFairfax$6K
- Ranjit CheriyanFairfax$4K
- Ramon MendezWoodbridge$791K
- Sandeep MagoonNorfolk$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.